Какова цена за GenSight Biologics S.A. (SIGHT)

Цена за GenSight Biologics S.A. (SIGHT) Это $0.12952814

Какова рыночная капитализация для GenSight Biologics S.A. (SIGHT)

Рыночная капитализация для GenSight Biologics S.A. (SIGHT) Это $21.11M

GenSight Biologics S.A. (SIGHT) Коэффициент P/S

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Год	P/S	Изменить
Недостаточно данных для указанных дат.

Год

P/S

Изменить

Недостаточно данных для указанных дат.

Компания	P/S	Разница P/S	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Moderna, Inc. MRNA.US	11.28	-	US
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH

Компания

P/S

Разница P/S

Страна